Summary
Bombesin/gastrin-releasing peptides (BN/GRP) were shown to bind selectively to cell surface receptors, stimulating the growth of various types of malignancies in murine and human models. The novel BN/GRP synthetic receptor antagonist, RC-3095, was able to produce long-lasting tumor regressions in murine and human tumor models in vitro and in vivo. Animal toxicology studies showed no detectable organ toxicity apart from local irritation at the injection site. The purpose of this study was to determine the safety and feasibility of the administration of RC-3095 by daily subcutaneous injections in patients with advanced and refractory solid malignancies. Twenty-five patients received RC-3095 once or twice-daily at doses ranging from 8 to 96 ug/kg. Dose was escalated in groups of 3–5 patients per dose level. The only toxicity observed was local discomfort in the injection site at the highest doses. A single dose administration of RC-3095 at the highest dose level (96 ug/kg) was tested in a clearly hypergastrinemic individual with the Zollingen-Ellison syndrome and produced a decrease in plasma gastrin down to 50% of basal levels in 6 h. There was no objective tumor responses in patients included in the study. A short-lasting minor tumor response was observed in a patient with a GRP-expressing progressive medullary carcinoma of the thyroid. Due to problems with the analytical method, plasma pharmacokinetic data was obtained only from two patients included at the highest dose level. In these patients, RC-3095 reached plasma concentrations >100 ng/mL for about 8 h, which were within therapeutic levels on the basis of prior data obtained in mice and rats. The plasma elimination half-life was between 8.6–10.9 h. Due to the occurrence of local toxicity at the injection site, the dose escalation procedure could not be fully evaluated up to a maximum tolerated dose. Thus, a recommended dose of RC-3095 for Phase II trials could not be clearly established. Considering the novelty of its mechanism of action and impressive preclinical anti-tumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations, and analogues with a more favorable pharmacokinetics are warranted.
Similar content being viewed by others
References
Ohki-Hamazaki H, Iwabuchi M, Maekawa F (2005) Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 49:293–300
Cuttitta F, Carney DN, Mulshine J, et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316:823–836
Nelson J, Dornelly M, Walker B, Gray J, Shaw C, Murphy RF (1991) Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer 63:933–936
Bologna M, Gestuccia C, Muzi P, Ciomei M (1989) Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714–1720
Carney DN, Cuttitta F, Moody TW, Minna JD (1987) Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47:821–825
Sun B, Schally AV, Halmos G (2000) The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 90:77–84
Qin Y, Ertl T, Cai R-Z, Halmos G, Schally AV (1994) Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 54:1035–1041
Hajri A, Balboni G, Koenig M, Garaud JC, Damge C (1992) Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res 52:3726–2732
Kelley MJ, Linnoila RL, Avis IL, Georgiadis MS, Cuttita F, Mulshine JL, et al. (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256–261
Cai R-Z, Radulovic S, Pinski J, Nagy A, Redding TW, Olsen DB, Schally AV (1992) Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides 13:267–271
Cai R-Z, Reile H, Armatis P, Schally AV (1994) Potent BN antagonists with C-terminal LeuΨ(CH2N)Tac-NH2 or its derivatives. Proc Natl Acad Sci USA 91:12664–12668
Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV (1992) High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regul Pept 41(3):185–193
Kiaris H, Schally AV, Sun B, Armatis P, Groot K (1999) Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene 18:7168–7173
Yano T, Pinski J, Groot K, Schally AV (1992) Stimulation and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52:4545–4547
Qin Y, Halmos G, Cai R-Z, Szoke B, Ertl T, Schally AV (1994) Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol 120:519–528
Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K (2000) Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists. Br J Cancer 83:906–913
Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV (1998) Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the level and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 83:1335–1343
Bajo AM, Schally AV, Groot K, Szepeshazi K (2004) Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 90(1):245–252
Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE (1997) A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MTX mouse mammary cancers. Proc Natl Acad Sci USA 94:10913–10918
Pereira AS, Di Leone L, Souza FH, Lilla S, Richter M, Schwartsmann G, De Nucci G (2005) Quantification of the bombesin/gastrin releasing peptide antagonist RC-3095 by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 816(1–2):321–32620
Pinski J, Reile H, Halmos G, Groot K, Schally AV (1994) Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 54:169–174
Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV (1994) Inhibition of growth of MKN-45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing peptide antagonist (RC-3095) and somatostain analog RC-160. Int J Cancer 57:574–580
Liebow C, Crean D, Lee MT, et al. (1994) Synergistic effects of bombesin and epidermal growth factor on cancers. Proc Natl Acad Sci 91:3804–3808
Schwartsmann G (2004) Dexamethasone and gastrin-relasing peptide receptors in human lung cells. Lung Cancer 46:129
Radulovic S, Miller G, Schally AV (1991) Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 51:6006–6009
Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T (1994) Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 33:693–701
Roesler R, Henriques JA, Schwartsmann G (2004) Neuropeptides and anxiety disorders: Bombesin receptors as novel therapeutic targets. Trends Pharmacol Sci 25:241–242
Roesler R, Kopschina MI, Rosa RM, Henriques JA, Souza DO, Schwartsmann G (2004) RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 13:35–41
Roesler R, Lessa D, Venturella R, Vianna MR, Luft T, Henriques JA, Izquierdo I, Schwartsmann G (2004) Bombesin/gastrin-releasing peptide receptors in the basolateral amygdale regulate memory consolidation. Eur J Neurosci 19:1041–1045
Shirahige Y, Cai R-Z, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV (1994) Inhibitory effect of bombesin gastrin-releasing peptide (GRP) antagonists RC-3095-II and RC-3095 on MCF7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother 48:465–472
Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S (1992) Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst 84:1915–1922
Szepeshazi K, Schally AV, Groot K, Halmos G (1993) Effect of bombesin, gastrin-releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 54:282–289
Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV (1994) Inhibitory effect of bombesin/gastrin releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer 73:1229–1238
Ide A, Ashizawa K, Ishikawa N, Ishii R, Ando T, Abe Y, Sera N, Usa T, Tominaga T, Ejima E, Nakashima M, Ito K, Ito K, Eguchi K (2001) Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma. Thyroid 11:1055–1061
Weber CJ, O’Dorisio TM, Howe B, D’Agati V, Ward L, Russell J, Feind CR (1991) Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactivities in human parathyroid glands. Surgery 110(6):1078–1985
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schwartsmann, G., DiLeone, L.P., Horowitz, M. et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 24, 403–412 (2006). https://doi.org/10.1007/s10637-006-6886-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-006-6886-5